The five-year event-free survival rate of non-MLL-r ALL can approach 60–96% in infants (<1 year of age), but is significantly lower in MLL-r infant ALL patients—only 34–39% depending on treatment protocols (Hilden et al., 2006; Tomizawa et al., 2007). This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.